Why Selective IL-23p19 Blockade Changed IBD Treatment

Selective targeting of the p19 subunit of IL-23 disrupts the downstream JAK-STAT3 signalling cascade that drives Th17 cell differentiation and mucosal inflammation in both ulcerative colitis and Crohn’s disease — without compromising the protective IL-12–mediated immunity that dual p40 inhibitors like ustekinumab suppress. This mechanistic distinction, confirmed in studies published in Nature-indexed immunology journals, is the scientific foundation on which mirikizumab, risankizumab, and guselkumab all compete.

IL-23 operates through multiple cellular effectors in the intestinal lamina propria: CD4+ T helper cells, gamma-delta T cells, innate lymphoid cell type 3 (ILC3) populations, and myeloid cells. Selective p19 blockade modulates ILC3 function while inhibiting production of IL-17A, IL-17F, IL-22, and TNF in colonic mucosa. The result is mucosal healing — endoscopic normalization and histological remission — which has emerged as the primary endpoint benchmark across all modern IBD trials.

Unlike ustekinumab’s dual p40 blockade, selective p19 inhibition maintains protective IL-12 immunity while dampening pathological IL-23–driven cascades. This has translated into a favorable safety profile across all three p19-selective agents — a competitive commonality that means differentiation must be sought elsewhere: in dosing convenience, biomarker response depth, and real-world evidence generation.

LUCENT Trials and the Omvoh Approval Story

The LUCENT-1 and LUCENT-2 trials are the regulatory backbone of mirikizumab’s approval: a 12-week induction phase (LUCENT-1) followed by a 40-week maintenance phase (LUCENT-2), both demonstrating statistically significant improvements in clinical remission, endoscopic response, and mucosal healing versus placebo in patients with moderately to severely active ulcerative colitis. These trials formed the basis for both the US FDA approval and the EMA approval, both granted in 2023.

The dosing regimen established in LUCENT — 300 mg IV every 4 weeks for induction, transitioning to 200 mg subcutaneous every 4 weeks for maintenance — creates a practical IV-to-SC bridge that Lilly’s commercial messaging has emphasised as a patient convenience differentiator. The subcutaneous maintenance formulation reduces infusion centre burden and supports at-home administration, which matters in competitive formulary negotiations with pharmacy benefit managers.

Lilly’s commercial launch positions Omvoh against risankizumab (Skyrizi, AbbVie) and vedolizumab as the primary competitive threats in UC, with guselkumab anticipated as a near-term entrant pending Phase 3 data readouts. Commercial messaging emphasises the IV-to-SC dosing transition, mucosal healing data, and suitability for biologic-experienced patients — a population that represents a significant share of the addressable UC market.

VIVID-1 and the Crohn’s Disease Label Expansion

In the VIVID-1 Phase 3 trial, mirikizumab met primary endpoints of clinical remission at both induction and maintenance phases in Crohn’s disease — a result that positions Lilly for a CD label expansion that would substantially broaden Omvoh’s addressable patient population. The CD indication would place mirikizumab in direct competition with risankizumab, which is already approved for CD, and would anticipate guselkumab’s own CD development programme.

The safety analysis from VIVID-1 revealed a generally favorable profile consistent with observations from the UC indication — a reassuring finding for prescribers and payers evaluating Omvoh for a patient population that is often more heavily biologic-experienced and treatment-refractory than the typical UC cohort. Biomarker analyses from the mirikizumab programme have also examined mucosal cytokine normalisation and histological remission in both UC and CD, providing mechanistic depth that supports differentiation arguments in payer submissions.

“Selective IL-23p19 blockade preserves IL-12–mediated protective immunity while dampening pathological IL-23–driven cascades — a mechanistic advantage that underpins the favorable safety profiles observed across mirikizumab’s UC and CD trial programmes.”

Mirikizumab’s Crohn’s disease development builds on a mechanistic rationale established in the UC programme: IL-23 signalling in CD operates through the same ILC3 and Th17 effector pathways, with IL-23 induction linked to intestinal barrier dysfunction and dysbiosis-associated inflammation. The stromal cell populations that perpetuate IL-23–driven inflammation in CD are also modulated by selective p19 blockade, providing a mechanistic basis for the clinical activity observed in VIVID-1.

Guselkumab and the Crowded IL-23p19 Field

Guselkumab (Tremfya, Janssen/J&J) is the most immediate competitive threat to mirikizumab’s IBD market position: already approved for psoriasis and psoriatic arthritis, it demonstrated significant clinical remission and endoscopic improvement versus placebo at both 200 mg and 400 mg IV doses in the QUASAR Phase 2 UC induction study, positioning it directly for Phase 3 development in UC and CD. According to EMA regulatory precedent, Phase 2 UC data of this quality typically support Phase 3 programme design within 12–18 months.

Network meta-analyses comparing the three leading anti-IL-23p19 agents show broadly comparable efficacy signals, with no definitive head-to-head superiority data available from completed trials. Indirect comparisons suggest similar rates of clinical remission and endoscopic response across mirikizumab, risankizumab, and guselkumab. The three agents also differ in their binding kinetics to IL-23p19, Fc isotype engineering, and half-lives — structural distinctions that have not yet translated into clinically meaningful efficacy differences but may influence dosing interval optimisation.

Guselkumab’s established formulary presence in dermatology under the Tremfya brand (psoriasis and psoriatic arthritis) may give Janssen significant contracting leverage upon IBD approval — a dynamic that analysts have identified as a potential competitive threat to both mirikizumab and risankizumab. According to FDA precedent, cross-indication formulary leverage has previously accelerated market access for dermatology biologics entering the gastroenterology space.

Real-World Evidence, Payer Dynamics, and Commercial Ramp

A multicenter European real-world study — among the first large-scale post-approval datasets for mirikizumab — evaluated outcomes in patients with moderately to severely active UC across both biologic-experienced and biologic-naive populations. Results indicated significant clinical benefit across different prior-therapy backgrounds, with a favorable short-term safety profile. This real-world evidence is strategically important for Lilly: it extends the LUCENT trial data into a more heterogeneous patient population and provides the payer-facing evidence needed to compete against risankizumab’s established formulary position.

Payer access dynamics present a structural challenge for mirikizumab. In the US, risankizumab entered IBD formularies with significant contracting leverage derived from its combined dermatology and gastroenterology portfolio. Mirikizumab faces step-therapy requirements in many commercial plans, defaulting to biologics with established prior authorisation pathways. This means that even with comparable or superior clinical data, Omvoh’s commercial ramp may be constrained by payer access barriers in the near term.

Strategic contracting with pharmacy benefit managers has been identified as a key competitive lever. Lilly’s commercial messaging emphasises the IV-to-SC dosing transition and mucosal healing data — both of which resonate with gastroenterologists — but the payer conversation requires a different evidence package: real-world outcomes data, health economic modelling, and step-therapy exemption arguments for biologic-experienced patients who have failed prior lines of therapy.

Risankizumab’s established presence — approved for both UC and CD — gives AbbVie a portfolio argument that Lilly cannot yet match until the Crohn’s disease label expansion is secured. The biologics market in IBD is being reshaped by the selective IL-23 inhibitors as a class, according to published analyses, but within that class the commercial winner will be determined by a combination of real-world evidence depth, payer contracting skill, and the timing of indication expansions.

Combination Strategies and the Next Frontier

Emerging clinical trial designs are exploring combinations of IL-23 inhibitors with JAK inhibitors — notably upadacitinib — or with TNF inhibitors for patients with refractory IBD who have failed multiple prior lines of therapy. The mechanistic rationale is complementary pathway inhibition: IL-23 blockade reducing T cell and ILC3 activation while JAK inhibition suppresses cytokine signalling broadly across multiple inflammatory pathways.

Preliminary data from investigator-initiated trials support the feasibility of this combination approach. Dual biologic therapy with anti-IL-23 and anti-TNF is entering early-phase clinical evaluation, representing a potential new treatment paradigm for the most refractory IBD patients. For Lilly, the combination therapy space represents both a scientific opportunity and a commercial one: if mirikizumab can be established as the IL-23 backbone of combination regimens, it extends the drug’s commercial longevity beyond the current biologic monotherapy market.

The patent landscape around combination IL-23 inhibitor strategies is also evolving rapidly. Eli Lilly’s foundational patent for mirikizumab covers humanized monoclonal antibody compositions selectively binding IL-23p19, dosing regimens including IV induction and subcutaneous maintenance formulations, and companion biomarker methods — with priority dates tracing to early mirikizumab development. As the combination therapy space expands, new patent filings covering specific combination regimens, patient selection biomarkers, and formulation innovations will become increasingly important competitive assets. Organisations tracking this space can monitor it systematically through PatSnap’s innovation intelligence platform.

According to WHO global disease burden data, inflammatory bowel disease affects tens of millions of patients worldwide, with incidence rising across both established and emerging markets. The scale of the unmet need — particularly in biologic-experienced patients with inadequate responses to TNF inhibitors and integrin antagonists — means that the IL-23p19 inhibitor class, including mirikizumab, is entering a large and growing addressable market. The competitive dynamics among Lilly, AbbVie, and Janssen will play out across multiple dimensions: clinical evidence, payer access, combination strategy, and geographic expansion.